AirFly: Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Change in Risk Stratification According to the COMPERA 2.0 Four-Stratum Model
研究概览
简要总结
This observational real-world study aims to evaluate the longitudinal clinical outcomes of adult patients with Group 3 pulmonary hypertension (PH), associated with chronic lung diseases such as interstitial lung disease, who are treated with inhaled iloprost in routine clinical practice.
Treatment options for Group 3 PH remain limited, and the use of pulmonary vasodilators is controversial due to potential worsening of gas exchange. Inhaled iloprost may provide a more selective approach by targeting well-ventilated lung regions. However, real-world data on its use in this population are scarce.
The primary objective of this study is to assess changes in clinical risk status over time using the COMPERA 2.0 four-stratum risk model. Secondary objectives include describing patient characteristics, treatment patterns, and the evolution of functional parameters and biomarkers, as well as documenting relevant clinical events such as hospitalizations, treatment escalation, and discontinuation.
The study will retrospectively analyze data from approximately 50 adult patients with confirmed Group 3 PH who received inhaled iloprost as part of their routine care in a specialized pulmonary hypertension center. No additional patient contact or interventions will occur.
详细描述
Group 3 pulmonary hypertension (PH), associated with chronic lung diseases such as interstitial lung disease, represents a common and clinically challenging PH phenotype, frequently associated with reduced exercise capacity, increased oxygen requirements, and higher mortality. Unlike pulmonary arterial hypertension (Group 1), where targeted therapies have demonstrated clear benefits, treatment options for Group 3 PH remain limited and are primarily focused on management of the underlying lung disease and supportive measures.
The use of systemic pulmonary vasodilators in this population is controversial due to the potential risk of worsening ventilation-perfusion mismatch and hypoxemia. Inhaled prostacyclin analogues may offer a more selective therapeutic approach by preferentially targeting well-ventilated lung regions, potentially mitigating these risks. Inhaled iloprost, approved for pulmonary arterial hypertension, has been used off-label in selected patients with Group 3 PH; however, available evidence is limited and largely derived from small or short-term studies. Data describing real-world patient profiles, treatment patterns, and longitudinal clinical outcomes remain scarce.
Risk stratification has become a key component of disease monitoring in pulmonary hypertension. The COMPERA 2.0 model, which incorporates clinical and non-invasive parameters into a four-stratum risk framework, has demonstrated sensitivity to detect prognostically meaningful changes over time.
This retrospective observational study aims to characterize the clinical evolution of patients with Group 3 PH treated with inhaled iloprost in routine practice. The primary focus is the longitudinal change in risk status according to the COMPERA 2.0 four-stratum model. In addition, the study will explore changes in functional parameters such as WHO functional class and six-minute walk distance, biomarker trends when available, patterns of iloprost use (including monotherapy or combination therapy), and the occurrence of relevant clinical events such as hospitalizations, treatment escalation, and treatment discontinuation.
Data will be obtained from existing medical records of patients followed in a specialized pulmonary hypertension center, without additional patient contact or intervention.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Diagnosis of group 3 pulmonary hypertension confirmed by right heart catheterization, defined as mean pulmonary artery pressure >20 mmHg, pulmonary artery wedge pressure ≤15 mmHg, and pulmonary vascular resistance >2 Wood units
- •Presence of documented underlying chronic lung disease (e.g., interstitial lung disease confirmed by high-resolution computed tomography with restrictive pattern on pulmonary function testing, or chronic obstructive pulmonary disease)
- •Use of inhaled iloprost for a minimum of 3 months, documented in medical records
- •Availability of baseline clinical data (at initiation of inhaled iloprost) and at least one follow-up assessment
排除标准
- •Pulmonary hypertension from other clinical groups (Groups 1, 2, 4, or 5) as the predominant diagnosis
- •Insufficient clinical information in medical records to allow characterization or longitudinal assessment
研究组 & 干预措施
Group 3 Pulmonary Hypertension Treated With Inhaled Iloprost
Adults (≥18 years) with group 3 pulmonary hypertension (PH due to chronic lung disease and/or hypoxia) followed at a specialized pulmonary circulation outpatient clinic who received inhaled iloprost during routine clinical care. Group 3 PH was confirmed by right heart catheterization according to current hemodynamic criteria and in the presence of documented underlying lung disease (e.g., interstitial lung disease or chronic obstructive pulmonary disease).
结局指标
主要结局
Change in Risk Stratification According to the COMPERA 2.0 Four-Stratum Model
时间窗: From baseline (initiation of inhaled iloprost) through available follow-up assessments during routine clinical care (follow-up of 3 to 6 months)
Primary outcome is the longitudinal change in clinical risk category assessed using the COMPERA 2.0 four-stratum model (low, intermediate-low, intermediate-high, high risk). Risk status will be determined based on available clinical variables (World Health Organization functional class, 6-minute walk distance, and BNP or NT-proBNP levels, when available). The analysis will evaluate the proportion of patients who demonstrate improvement, stability, or worsening of risk category during follow-up compared with baseline (defined as initiation of inhaled iloprost).
次要结局
- Change in World Health Organization (WHO) Functional Class(From baseline (initiation of inhaled iloprost) through available follow-up assessments during routine clinical care (follow-up of 3 to 6 months))
- Change in 6-Minute Walk Distance (6MWD)(From baseline (initiation of inhaled iloprost) through available follow-up assessments during routine clinical care (follow-up of 3 to 6 months))
- Change in BNP or NT-proBNP Levels(From baseline (initiation of inhaled iloprost) through available follow-up assessments during routine clinical care (follow-up of 3 to 6 months))
- Clinical Events During Follow-up(From baseline (initiation of inhaled iloprost) through available follow-up assessments during routine clinical care (follow-up of 3 to 6 months))
研究者
Caio Júlio César dos Santos Fernandes
Pulmonologist, PhD
University of Sao Paulo General Hospital